Literature DB >> 12819903

-to: Nicoletti F, Conget L, Di Mauro M et al. (2002) Serum concentrations of the interferon-alpha-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 45:1107-1110.

M Rotondi, P Romagnani, A Brozzetti, F Santeusanio, M Serio, A Falorni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12819903     DOI： 10.1007/s00125-003-1134-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  6 in total

Review 1.  IDDM and autoimmune thyroid disease in the pediatric age group.

Authors:  R Lorini; G d'Annunzio; L Vitali; A Scaramuzza
Journal:  J Pediatr Endocrinol Metab       Date:  1996-03       Impact factor: 1.634

2.  Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies.

Authors:  G Gambelunghe; F Forini; S Laureti; G Murdolo; G Toraldo; F Santeusanio; P Brunetti; C B Sanjeevi; A Falorni
Journal:  Clin Endocrinol (Oxf)       Date:  2000-05       Impact factor: 3.478

3.  Elevated serum IP-10 levels observed in type 1 diabetes.

Authors:  A Shimada; J Morimoto; K Kodama; R Suzuki; Y Oikawa; O Funae; A Kasuga; T Saruta; S Narumi
Journal:  Diabetes Care       Date:  2001-03       Impact factor: 19.112

Review 4.  Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field.

Authors:  M Rotondi; E Lazzeri; P Romagnani; M Serio
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

5.  Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease.

Authors:  Paola Romagnani; Mario Rotondi; Elena Lazzeri; Laura Lasagni; Michela Francalanci; Andrea Buonamano; Stefano Milani; Paolo Vitti; Luca Chiovato; Massimo Tonacchera; Antonio Bellastella; Mario Serio
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

6.  Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease.

Authors:  F Nicoletti; I Conget; M Di Mauro; R Di Marco; M C Mazzarino; K Bendtzen; A Messina; R Gomis
Journal:  Diabetologia       Date:  2002-06-21       Impact factor: 10.122
  6 in total
  3 in total

1.  Impaired CD4 and CD8 T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children.

Authors:  M Hedman; M Faresjö; S Axelsson; J Ludvigsson; R Casas
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

2.  Large-Scale Discovery and Validation Studies Demonstrate Significant Reductions in Circulating Levels of IL8, IL-1Ra, MCP-1, and MIP-1β in Patients With Type 1 Diabetes.

Authors:  Sharad Purohit; Ashok Sharma; Diane Hopkins; Leigh Steed; Bruce Bode; Stephen W Anderson; John Chip Reed; R Dennis Steed; Tao Yang; Jin-Xiong She
Journal:  J Clin Endocrinol Metab       Date:  2015-07-09       Impact factor: 5.958

Review 3.  Chemokines as Drivers of the Autoimmune Destruction in Type 1 Diabetes: Opportunity for Therapeutic Intervention in Consideration of an Optimal Treatment Schedule.

Authors:  Urs Christen; Ruta Kimmel
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-19       Impact factor: 5.555
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.